Horizon Pharma plc (HZNP) Shares are Up 4.2%

Horizon Pharma plc (HZNP) : Traders are bullish on Horizon Pharma plc (HZNP) as it has outperformed the S&P 500 by a wide margin of 4.82% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.76%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.2% in the last 1 week, and is up 7.43% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Horizon Pharma plc (NASDAQ:HZNP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $19.61 and $19.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $20.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $20.10, notching a gain of 3.29% for the day. The total traded volume was 4,801,396 . The stock had closed at $19.46 on the previous day.

The stock has recorded a 20-day Moving Average of 5.29% and the 50-Day Moving Average is 12.02%. Horizon Pharma plc is up 49.89% in the last 3-month period. Year-to-Date the stock performance stands at -7.25%.

Horizon Pharma plc (HZNP) stock is expected to deviate a maximum of $8.46 from the average target price of $32.29 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $45 and the most muted being $24.


Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.